Grace Amber, Sahu Rajnish, Owen Donald R, Dennis Vida A
Department of Biological Sciences, Alabama State University, Montgomery, AL, United States.
Owen Biosciences Inc., Baton Rouge, LA, United States.
Front Microbiol. 2022 Oct 13;13:1023523. doi: 10.3389/fmicb.2022.1023523. eCollection 2022.
is a ubiquitous, motile, gram-negative bacterium that has been recently identified as a multi-drug resistant pathogen in critical need of novel therapeutics. Of the approximately 5,000 strains, PAO1 and PA14 are common laboratory reference strains, modeling moderately and hyper-virulent phenotypes, respectively. PAO1 and PA14 have been instrumental in facilitating the discovery of novel drug targets, testing novel therapeutics, and supplying critical genomic information on the bacterium. While the two strains have contributed to a wide breadth of knowledge on the natural behaviors and therapeutic susceptibilities of , they have demonstrated significant deviations from observations in human infections. Many of these deviations are related to experimental inconsistencies in laboratory strain environment that complicate and, at times, terminate translation from laboratory results to clinical applications. This review aims to provide a comparative analysis of the two strains and potential methods to improve their clinical relevance.
是一种普遍存在、具有运动性的革兰氏阴性菌,最近被确定为急需新型疗法的多重耐药病原体。在大约5000个菌株中,PAO1和PA14是常见的实验室参考菌株,分别模拟中度和高毒力表型。PAO1和PA14在促进新型药物靶点的发现、测试新型疗法以及提供该细菌的关键基因组信息方面发挥了重要作用。虽然这两种菌株为关于该菌自然行为和治疗易感性的广泛知识做出了贡献,但它们与人类感染中的观察结果存在显著偏差。其中许多偏差与实验室菌株环境中的实验不一致有关,这些不一致使从实验室结果到临床应用的转化变得复杂,有时甚至导致转化终止。本综述旨在对这两种菌株进行比较分析,并提出提高其临床相关性的潜在方法。